Lenalidomide Grindeks (Lenalidomide)

Lenalidomide exerts its therapeutic effect by binding to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex. This binding changes the complex’s substrate specificity, leading to ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos. The resulting loss of these proteins produces anti‑angiogenic, immunomodulatory, and anti‑proliferative actions that suppress malignant plasma‑cell growth and restore immune surveillance.

The specific dose of Lenalidomide Grindeks is determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and concomitant therapies. Dosing regimens are individualized and may involve daily oral administration for a defined treatment cycle, followed by a rest period. Patients should follow the exact instructions provided by their healthcare professional.

Lenalidomide is classified as Pregnancy Category X, indicating it is contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential must use effective contraception before, during, and after treatment. The drug is also not recommended for breastfeeding mothers, as it may be excreted in breast milk and affect the infant. Consultation with a specialist is essential for risk management.

To request Lenalidomide Grindeks, visit the product page on the GNH India website (gnhindia.com) and submit an enquiry specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will ask for trade or institutional credentials. After verification, the sales team provides pricing, availability, shipping details—including any required cold‑chain handling—and assists with import documentation.

The primary alternative to lenalidomide in the same therapeutic class is thalidomide, another immunomodulatory agent. Lenalidomide generally offers a more favorable safety profile, with lower rates of peripheral neuropathy and constipation, while maintaining comparable efficacy in multiple myeloma. However, both drugs share risks such as thrombosis and hematologic toxicity, and the choice depends on individual patient factors and physician judgment.

Lenalidomide Grindeks should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the product in its original packaging to protect it from moisture, light, and humidity. Do not refrigerate or freeze the tablets. Ensure that the storage area is dry and that the medication is kept out of reach of children and pets.

Lenalidomide Grindeks is taken orally, usually as a tablet swallowed whole with water. The medication is typically administered once daily on a schedule defined by the treating physician, often in cycles that include a treatment period followed by a rest period to allow bone‑marrow recovery. Patients should follow the dosing timetable prescribed and avoid missing doses without consulting their clinician.

The most serious risks of lenalidomide include severe hematologic toxicities such as neutropenia and thrombocytopenia, which can increase infection and bleeding risk. Thromboembolic events like deep‑vein thrombosis or pulmonary embolism are also significant concerns, especially when combined with other agents. Additionally, there is a risk of secondary primary malignancies and fetal toxicity, making pregnancy avoidance critical.

Lenalidomide is contraindicated in pregnant women and in individuals who are not using effective contraception. Patients with uncontrolled infections, severe hepatic impairment, or known hypersensitivity to lenalidomide or its excipients should avoid the drug. Those with a history of thromboembolic disease require careful assessment, and the medication should be used only under the supervision of a qualified hematologist or oncologist.